Radium Ra 223 dichloride

Drug Overview

Radium Ra 223 dichloride is a breakthrough radioactive therapeutic agent designed to treat advanced cancer that has spread to the bones. It is a “Smart Drug” classified as a Targeted Alpha-Emitter. This means it mimics common minerals in the body to find cancer hidden in the bones and destroys it using high-energy radiation that travels only a very short distance.

For patients and healthcare providers, this medication represents a corporate standard in precision oncology. Because it specifically targets areas where bone is being rapidly rebuilt by cancer, it delivers a powerful punch to the tumor while causing minimal damage to the surrounding healthy organs. This targeted approach helps patients maintain a better quality of life while fighting aggressive disease.

• Generic Name: Radium Ra 223 dichloride
• US Brand Names: Xofigo
• Drug Class: Therapeutic Alphaparticle-Emitting Radioactive Pharmaceutical
• Route of Administration: Intravenous (IV) Injection
• FDA Approval Status: FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

To understand how Radium Ra 223 dichloride works, imagine the drug as a “Trojan Horse.” Your body naturally uses calcium to build and repair bones. Radium is in the same chemical family as calcium, so the body cannot tell the difference between the two.

At the molecular level, the process follows these precise steps:

1. Bone Targeting: Cancer cells in the bone cause high “bone turnover,” meaning the bone is constantly being broken down and rebuilt. Radium Ra 223 mimics calcium and is naturally drawn to these high-turnover areas (bone metastases).
2. Alpha Particle Emission: Once the radium is incorporated into the bone matrix, it begins to decay. During this decay, it releases alpha particles.
3. High-Energy Destruction: Alpha particles are heavy and carry a very high amount of energy. When they hit the DNA of a cancer cell, they cause “Double-Strand Breaks.” This is a lethal type of damage that the cancer cell cannot repair.
4. Short Range Precision: A unique feature of alpha radiation is its short range—less than 100 micrometers (about the thickness of 2 to 10 cells). This acts as a “biological shield,” ensuring the radiation kills the cancer cells but does not reach the healthy bone marrow or nearby organs like the heart or lungs.

FDA-Approved Clinical Indications

Radium Ra 223 is specifically approved for the treatment of advanced prostate cancer that has reached a specific stage.

Oncological Uses

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): For patients whose cancer has spread to the bones and is causing symptoms, but has not spread to other internal organs (like the liver or lungs).
• Symptomatic Bone Metastases: Specifically used when the cancer no longer responds to medical or surgical treatments that lower testosterone.

Non-Oncological Uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Radium Ra 223 is administered as a slow intravenous injection by a professional team in a nuclear medicine or radiation oncology department.

Dose Adjustments:

• Renal/Hepatic Insufficiency: No dose adjustments are required for patients with kidney or liver impairment, as the drug is primarily eliminated through the intestines and is not processed heavily by these organs.

Clinical Efficacy and Research Results

Clinical studies updated between 2020 and 2025 (including follow-up data from the ALSYMPCA trial) confirm that Radium Ra 223 significantly improves patient outcomes.

• Overall Survival (OS): Clinical data shows that Radium Ra 223 extends overall survival by an average of 3.6 months compared to a placebo, with some patients living significantly longer.
• Skeletal Events: Research indicates a 33% reduction in the risk of serious bone complications, such as fractures or the need for bone surgery, compared to standard care.
• Quality of Life: In recent 2024 studies, patients reported a meaningful delay in the time it took for bone pain to worsen, allowing them to remain active for a longer period during treatment.
• Disease Progression: Numerical data suggests a significant reduction in the levels of Alkaline Phosphatase (ALP), a blood marker that shows how active the cancer is in the bone.

Safety Profile and Side Effects

Black Box Warning:

None. (However, there is a strong warning regarding use in combination with abiraterone and prednisone/prednisolone due to an increased risk of fractures).

Common Side Effects (>10%)

• Nausea and Vomiting: Usually mild and occurs shortly after injection.
• Diarrhea: Often manageable with over-the-counter medications.
• Peripheral Edema: Swelling in the legs or ankles.
• Low Blood Counts (Cytopenia): Especially low red blood cells (anemia) and platelets.

Serious Adverse Events

• Bone Marrow Suppression: Severe drops in white blood cells (neutropenia) which increase infection risk.
• Osteonecrosis of the Jaw: A rare but serious condition involving the death of bone tissue in the jaw.
• Increased Fracture Risk: If used incorrectly with certain other hormone therapies.

Management Strategies

• Blood Monitoring: Complete Blood Count (CBC) tests are performed before every injection to ensure it is safe to proceed.
• Hydration: Patients are encouraged to drink plenty of fluids to help the body eliminate any unabsorbed radioactive material through the bowel.

Research Areas

In the fields of Immunotherapy and Regenerative Medicine, researchers are investigating “Radiopharmaceutical Combinations.” Scientists are studying whether the cell death caused by Radium Ra 223 acts as an “immune primer,” making the tumor more visible to Checkpoint Inhibitors. There is also early research into using bone-protecting agents to help the bone “regenerate” and strengthen after the cancer cells have been cleared by the radium.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Baseline CBC: To check white blood cell, red blood cell, and platelet counts.
• ALP Levels: To establish a baseline for bone turnover activity.
• PSA Levels: To monitor the status of the prostate cancer.

Precautions During Treatment

• Radiation Safety: While the radiation range is very short, patients should practice good hygiene (flushing twice, washing hands) for one week after each injection to safely manage body fluids.
• Fracture Prevention: Patients should continue taking bone-strengthening agents (like zoledronic acid) as prescribed by their doctor.

“Do’s and Don’ts” List

• Do stay consistent with the 4-week schedule; missing a dose can allow the cancer to resume bone destruction.
• Do report any new or worsening bone pain to your oncology team immediately.
• Don’t assume you are “contagious”—the type of radiation used (alpha) does not travel out of your body to others.
• Don’t start new medications without consulting your oncologist, especially other hormonal therapies.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Radium Ra 223 dichloride is a radioactive prescription medication. Always consult with a licensed oncologist or nuclear medicine specialist regarding your specific diagnosis and treatment plan. This content reflects clinical data available as of 2026.